Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Primary Purpose
Interstitial Cystitis
Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LiRIS 400 mg
LiRIS Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Interstitial Cystitis
Eligibility Criteria
Inclusion Criteria
Blinded study:
- Women age 18 and over
- Diagnosed with Interstitial Cystitis as defined by protocol
- Able to report IC symptoms of bladder pain, voiding habits, as required by protocol, and record in diary
- Able to comply with visit schedule and diary completion at home
Open-label Extension:
- Must have completed the blinded study prior to screening for the Open-label extension
Exclusion Criteria (Blinded and Open-Label Extension):
- Pregnant or lactating women
- History or presence of any condition that would make it difficult to accurately evaluate bladder symptoms
- Bladder or urethral abnormality that would prevent safe insertion of investigational product
- Requiring medication not allowed per study protocol
Sites / Locations
- Citrus Valley Medical Research , Inc.
- Atlantic Urological Associates
- University of Kansas Medical Center
- The UrogynecologyCenter, LLC
- Female Pelvic Medicine & Urogynecology Institute of MI
- William Beaumont Hospitals
- North Shore - Long Island Jewish Heath System - Monter Cancer Center
- Premier Medical Group of the Hudson Valley PC
- Premier Medical Group of the Hudson Valley PC
- Alliance Urology Specialists, PA
- Wake Forest Baptist Health
- MetroHealth Medical Center
- Medical University of South Carolina
- Carolina Urologic Research Center
- Volunteer Research Group, University of Tennessee Medical Center
- Exdeo Clinical Research Inc.
- Centre for Applied Urological Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
LiRIS 400 mg
LiRIS Placebo
Arm Description
LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
Outcomes
Primary Outcome Measures
Change From Baseline in Participant Reported Average Bladder Pain on a Numerical Rating Scale (NRS)
Participants rated their bladder pain over the previous 24 hours in an electronic diary using a horizontal line NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. Bladder pain was averaged over a period of 3 days. A negative change from Baseline indicates improvement.
Secondary Outcome Measures
Change From Baseline in Total Daily Voids
Participants recorded number of daily voids (day-time and night-time daily voids) in a 3 day Voiding Frequency electronic diary. The total number of daily voids was averaged over a period of 3 full days. A negative change from Baseline indicates improvement.
Change From Baseline in Night-Time Daily Voids
Participants recorded number of night-time daily voids in a 3 day Voiding Frequency electronic diary. The total number of night-time daily voids was averaged over a period of 3 days. A negative change from Baseline indicates improvement.
Change From Baseline in Average Void Volume Per Micturition
Participants recorded the amount of each void in millimeters (mL) in an electronic diary. The total amount of void per micturition (each void) was averaged over a period of 24 days. A negative change from Baseline indicates improvement.
Change From Baseline in Post-Void Bladder Pain
Participants rated their bladder pain immediately completing voiding in an electronic diary using a horizontal line NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. The average of the data from the first 5 voids prior to Baseline and the 3 days prior to Day 12 were averaged for analyses. A negative change from Baseline indicates improvement.
Change From Baseline in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) Score
The ICSI is a participant reported questionnaire to rate their symptoms by answering 4 questions. Question (Q) 1 and 2 (urine urgency) using a 6-point scale where: 0=Not at All to 5=Almost Always. Q3 (night-time voids) using a 6-point scale where: 0=None to 5=5 or More Times. Q4 (pain and burning) using a 6-point scale where: 0=Not at All to 5=Usually. The total score is the sum of the individual scores for a total possible score of 0 (best) to 20 (worst). A negative change from Baseline indicates improvement.
Change From Baseline in O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) Score
The ICPI is a participant reported questionnaire to rate their problems in the following 4 areas: Frequent urination; Getting up at Night to Urinate: Urination with little warning; Burning pain and discomfort. Questions are answered on a 5-point scale where: 0=No Problem to 4=Big Problem. The total score is the sum of the individual scores for a total possible score of 0 (best) to 20 (worst). A negative change from Baseline indicates improvement.
Change From Baseline in Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)
The BPIC-SS is a participant reported questionnaire consisting of 8 items. Questions (Q) 1-5 (How often urination because of pain; Need to urinate after just urinating; How often urination to avoid worse pain; How often feeling of pressure in bladder; How often pain in bladder) answered on a 5-point scale where: 0=Never to 4=Always. Q 6-7 (Bothered by frequent Day-time urination; Bothered by Night-time urination) answered on a 5-point scale where: 0=Not At All to 4=A Great Deal. Q8 (pain) rated on a NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. The Total Score is the sum of the individual questionnaire of all 8 items for a total possible score of 0 (best) to 38 (worst). A negative change indicates improvement.
Change From Baseline in Brief Pain Inventory (BPI)
The BPI is a 7-item participant completed questionnaire. The participant answered questions as to how pain interfered with: General Activity, Mood, Walking Ability, Normal work, Relations with other people, Sleep and Enjoyment of life. Questions were answered on an 11-point scale where: 0=Does not interfere to 10=Completely interferes. The total score is the average of the individual questionnaire items for a total possible score of 0 (best) to 10 (worst). A negative change from Baseline indicates improvement.
Full Information
NCT ID
NCT01824303
First Posted
March 31, 2013
Last Updated
December 16, 2015
Sponsor
Allergan
Collaborators
TARIS Biomedical, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01824303
Brief Title
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Official Title
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Terminated
Why Stopped
This study was terminated early due to company decision.
Study Start Date
March 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Allergan
Collaborators
TARIS Biomedical, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration.
Detailed Description
The study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned randomly (by chance) to LiRIS 400 mg or LiRIS placebo; subjects who complete this part and are eligible to continue, may participate in the open-label part in which all subjects receive LiRIS 400 mg.
In both parts of the study (blinded and open-label), LiRIS is inserted into the bladder during cystoscopy, remains in the bladder for 14 days, and is removed during cystoscopy. In addition to the 14 day period with the LiRIS/LiRIS Placebo, there is a screening period of up to 2 weeks and a follow up period of 4 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Interstitial Cystitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LiRIS 400 mg
Arm Type
Experimental
Arm Description
LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
Arm Title
LiRIS Placebo
Arm Type
Placebo Comparator
Arm Description
LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
Intervention Type
Drug
Intervention Name(s)
LiRIS 400 mg
Intervention Description
LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
Intervention Type
Other
Intervention Name(s)
LiRIS Placebo
Intervention Description
LiRIS Placebo contains lactose, inactive substance.
Primary Outcome Measure Information:
Title
Change From Baseline in Participant Reported Average Bladder Pain on a Numerical Rating Scale (NRS)
Description
Participants rated their bladder pain over the previous 24 hours in an electronic diary using a horizontal line NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. Bladder pain was averaged over a period of 3 days. A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 12
Secondary Outcome Measure Information:
Title
Change From Baseline in Total Daily Voids
Description
Participants recorded number of daily voids (day-time and night-time daily voids) in a 3 day Voiding Frequency electronic diary. The total number of daily voids was averaged over a period of 3 full days. A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in Night-Time Daily Voids
Description
Participants recorded number of night-time daily voids in a 3 day Voiding Frequency electronic diary. The total number of night-time daily voids was averaged over a period of 3 days. A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in Average Void Volume Per Micturition
Description
Participants recorded the amount of each void in millimeters (mL) in an electronic diary. The total amount of void per micturition (each void) was averaged over a period of 24 days. A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in Post-Void Bladder Pain
Description
Participants rated their bladder pain immediately completing voiding in an electronic diary using a horizontal line NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. The average of the data from the first 5 voids prior to Baseline and the 3 days prior to Day 12 were averaged for analyses. A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) Score
Description
The ICSI is a participant reported questionnaire to rate their symptoms by answering 4 questions. Question (Q) 1 and 2 (urine urgency) using a 6-point scale where: 0=Not at All to 5=Almost Always. Q3 (night-time voids) using a 6-point scale where: 0=None to 5=5 or More Times. Q4 (pain and burning) using a 6-point scale where: 0=Not at All to 5=Usually. The total score is the sum of the individual scores for a total possible score of 0 (best) to 20 (worst). A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) Score
Description
The ICPI is a participant reported questionnaire to rate their problems in the following 4 areas: Frequent urination; Getting up at Night to Urinate: Urination with little warning; Burning pain and discomfort. Questions are answered on a 5-point scale where: 0=No Problem to 4=Big Problem. The total score is the sum of the individual scores for a total possible score of 0 (best) to 20 (worst). A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)
Description
The BPIC-SS is a participant reported questionnaire consisting of 8 items. Questions (Q) 1-5 (How often urination because of pain; Need to urinate after just urinating; How often urination to avoid worse pain; How often feeling of pressure in bladder; How often pain in bladder) answered on a 5-point scale where: 0=Never to 4=Always. Q 6-7 (Bothered by frequent Day-time urination; Bothered by Night-time urination) answered on a 5-point scale where: 0=Not At All to 4=A Great Deal. Q8 (pain) rated on a NRS by putting a mark on the line where: 0 (the far left of the line)=no pain to 10 (far right of the line)=worst pain imaginable. The Total Score is the sum of the individual questionnaire of all 8 items for a total possible score of 0 (best) to 38 (worst). A negative change indicates improvement.
Time Frame
Baseline, Day 27
Title
Change From Baseline in Brief Pain Inventory (BPI)
Description
The BPI is a 7-item participant completed questionnaire. The participant answered questions as to how pain interfered with: General Activity, Mood, Walking Ability, Normal work, Relations with other people, Sleep and Enjoyment of life. Questions were answered on an 11-point scale where: 0=Does not interfere to 10=Completely interferes. The total score is the average of the individual questionnaire items for a total possible score of 0 (best) to 10 (worst). A negative change from Baseline indicates improvement.
Time Frame
Baseline, Day 27
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Blinded study:
Women age 18 and over
Diagnosed with Interstitial Cystitis as defined by protocol
Able to report IC symptoms of bladder pain, voiding habits, as required by protocol, and record in diary
Able to comply with visit schedule and diary completion at home
Open-label Extension:
Must have completed the blinded study prior to screening for the Open-label extension
Exclusion Criteria (Blinded and Open-Label Extension):
Pregnant or lactating women
History or presence of any condition that would make it difficult to accurately evaluate bladder symptoms
Bladder or urethral abnormality that would prevent safe insertion of investigational product
Requiring medication not allowed per study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Curtis Nickel, MD
Organizational Affiliation
Queen's University/Kingston General Hospital/Ontario Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
Citrus Valley Medical Research , Inc.
City
Glendora
State/Province
California
ZIP/Postal Code
91741
Country
United States
Facility Name
Atlantic Urological Associates
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32114
Country
United States
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
The UrogynecologyCenter, LLC
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66209-2002
Country
United States
Facility Name
Female Pelvic Medicine & Urogynecology Institute of MI
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Facility Name
William Beaumont Hospitals
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Facility Name
North Shore - Long Island Jewish Heath System - Monter Cancer Center
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11040
Country
United States
Facility Name
Premier Medical Group of the Hudson Valley PC
City
Newburgh
State/Province
New York
ZIP/Postal Code
12550
Country
United States
Facility Name
Premier Medical Group of the Hudson Valley PC
City
Poughkeepsie
State/Province
New York
ZIP/Postal Code
12601
Country
United States
Facility Name
Alliance Urology Specialists, PA
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27403
Country
United States
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Carolina Urologic Research Center
City
Myrtle Beach
State/Province
South Carolina
ZIP/Postal Code
29572
Country
United States
Facility Name
Volunteer Research Group, University of Tennessee Medical Center
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
Exdeo Clinical Research Inc.
City
Abbotsford
State/Province
British Columbia
ZIP/Postal Code
V2S 3N6
Country
Canada
Facility Name
Centre for Applied Urological Research
City
Kingston
State/Province
Ontario
ZIP/Postal Code
K7L 3J7
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
We'll reach out to this number within 24 hrs